modelInosine
Extends from Pharmacolibrary.Drugs.ATC.D.D06BB05.
Information
| name: | Inosine | |
| ATC code: | D06BB05 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 42 | L |
| clearance: | 1.2 | L/h |
| other parameters in model implementation | ||
Inosine is a purine nucleoside that is produced by the deamination of adenosine. It has been explored as a therapeutic agent for various medical conditions, including neurological disorders such as multiple sclerosis and Parkinson's disease, as well as for its potential use in treating viral infections and as an immunomodulatory agent. Inosine is not widely approved as a pharmaceutical drug in many countries and is mostly available as a dietary supplement.
Pharmacokinetics
No published human pharmacokinetic parameters for inosine were identified. PK parameters reported here are only estimated based on its molecular similarity to other purine nucleosides (e.g., adenosine, guanosine) and basic physicochemical properties. Parameters are rough approximations for a typical adult following oral administration.
References
Staatz, CE, & Tett, SE (2007). Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clinical pharmacokinetics 46(1) 13–58. DOI:10.2165/00003088-200746010-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17201457
Li, H, et al., & McCune, JS (2014). Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20(8) 1121–1129. DOI:10.1016/j.bbmt.2014.03.032 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24727337
McHutchison, JG, et al., & Alam, J (2005). A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antiviral therapy 10(5) 635–643. PUBMED:https://pubmed.ncbi.nlm.nih.gov/16152757
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)